There are two significant risks to Crestor this year," Jeffries analyst Jeff Holford told the news service. "The first is that we will probably have the appeal hearing on the Crestor patent decision, which I think everyone has forgotten about." The other: The results of a head-to-head study against Lipitor come out later this year, and the consequences of a poor showing--and benefits of a good one--are obvious.
via fiercepharma.com
No comments:
Post a Comment